Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

  • August 2016 •
  • Report ID: 4100753
Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

Summary

Diabetes mellitus refers to a group of metabolic diseases characterized by chronic hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both of these (ADA, 2014). Under normal circumstances insulin is secreted by the pancreas and into the blood stream upon digestion of food, and subsequent absorption of glucose into the bloodstream. Here it acts to facilitate the absorption of glucose by target cells.

The pipeline for the disease cluster of diabetes and obesity is strong, with a notable rise in revenues expected over the forecast period, despite patent expiries for a number of key marketed drugs. The global market size for this disease cluster is anticipated to grow considerably over the forecast period, from USD70.8 Billion in 2015 to USD163.2 Billion in 2022, at a compound annual growth rate (CAGR) of 12.7%.

The growth of the disease cluster is driven not only by the rising global incidence of obesity, but also the subsequent effect that this has on T2DM incidence, given the intrinsic link between the two diseases. Furthermore, many products indicated for obesity are also indicated for T2DM, as combating obesity in T2DM patients improves diabetic symptoms, and it is these multiple-indication products that produce the greatest revenues and show the most promise as key future therapeutics.

According to Callum Dew, GBI Research, explains: “Recent approvals and pipeline products that are expected to be key players during the forecast period include Tresiba (insulin degludec), Invokana (canagliflozin) and NN-9535 (semaglutide). The disease cluster is dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and T2DM, and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications.”

An increasing pipeline presence for obesity-indicated products and overwhelming global media interest highlight the relevance of this indication and its future potential global revenues. However, the number of pharmacotherapeutic products and revenues for obesity are dwarfed by diabetes-indicated products. Given the status of obesity as a risk factor for T2DM, it is likely that the T2DM market will continue to rise with the rising obesity incidence.

The report “Global Diabetes and Obesity Drugs Market to 2022 - Insulin’s and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment” provides an introduction to the disease cluster of diabetes and obesity, and some detailed background information regarding the diseases. Information is also included regarding symptoms, etiology and pathophysiology, comorbidities and epidemiology.

In depth, it provides the following analysis -
- Provides an overview of the marketed products of diabetes and obesity, including product profiles of key marketed products, and revenue projections for each of these drugs.
- Helps to analyze the diabetes and obesity pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus separate analysis of T1DM, T2DM and obesity.
- Provides forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players.
- Assesses the company landscape for the disease cluster, with an analysis of the key players, the types of company involved, and whether the disease cluster comprises a large proportion of each company’s pipeline portfolio and total revenues.
- Analyses of trends in co-development and licensing deals relating to diabetes and obesity products. Some of the most prominent deals are discussed in detail.

Companies mentioned in this report: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co, AstraZeneca, Takeda,

Scope

- What are the current treatment options for diabetes and obesity?
- What are the common molecular targets of pipeline therapies, and how strongly do they overlap with the current market?
- Will the pipeline address unmet needs such as a lack of safe treatment options for diabetes and obesity patients?
- Which late-stage pipeline products are likely to impact the current market?
- How are revenues of key companies, targets and molecule types anticipated to change over the forecast period?
- Which companies are anticipated to be the most prominent players over the next seven years?
- How do licensing and co-development deals compare between diabetes and obesity?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the diabetes and obesity market in terms of the clinical and commercial standing of current dominant therapies. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the diabetes and obesity pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There is a strong contrast in the amount of pipeline activity for diabetes and obesity.
- Analyze how individual company, molecule type and molecular target revenues are anticipated to change over the forecast period, highlighting prominent companies and the most promising molecule types and targets.
- Identify which companies are the current key players for the disease cluster, and how this pattern is anticipated to change over the forecast period.
- Identify commercial opportunities in the diabetes and obesity deals landscape by analyzing trends in licensing and co-development deals by stage of development, molecule type and molecular target.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.